Thrombolytics,dextrans,oral anticoagulants.
LMWHs, adnesosine, sulfiinpyrazone, prostacyclin
NSAIDs, dypyridamole. ticlopodine,
Clopidogrel, frusemide, streptokinase,

  Prevention of early MI

 Bleeding,
Intracranial haemorrhage, thrombocytopenia,
Cardiovascular disturbances, shock,
Hypotension, phlebitis, fever

GI, genitourinary or other active abnormal bleeding within past 30 days
Stroke within past 30 days or history of haemorrhage stroke
Intracranial disease
Major surgery or severe trauma within past 8 weeks
Thrombocytopenia, prothrombin time > 1.2 times control or
INR  > 2.0
Severe hypotension. Several renal CrCl < 30ml/min or
Hepatic impairment
Lactation

Special precaution-
Monitor haematology before and during therapy
Stop immediately if thrombolytic therapy or emergency cardiac surgery required or
if uncontrollable bleeding occurs
Stop if platelet count falls below 100,000mm3
Renal insufficiency or hepatic impairment
Pregnancy

Date of Approval       1999

Indication-

Prevention of early MI

Dosage-


Initially- 180microgram/kg by i.v. bolus inj. followed by 2 microgram/kg per minute
by continous i.v. infusion for up to 72 hrs

If percutaneous coronary intervention is performed during therapy continue inf. for 20-24 hours
post-PCI    for a total max duration of therapy of 96 hours

Under 18 years not recommended

Contraindcated for use during pregnancy and lactation
Observe caution if required to be used